Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 13, 2020

SELL
$44.49 - $93.39 $244,116 - $512,430
-5,487 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$66.49 - $137.73 $364,830 - $755,724
5,487 New
5,487 $523,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $82.2M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.